Connect with us

Russia

Despite challenges, Russia progresses with vaccination at home and abroad

Published

on

image source: Kremlin.ru

President Vladimir Putin has praised the entire healthcare system, and particularly the hard-working team of scientists and specialists from different institutions for their efforts at research and creating a series of coronavirus vaccines for use against the coronavirus both at home and abroad. Three vaccines already registered in Russia, two of them – Sputnik V and EpiVacCorona – are produced in large quantities by Russian pharmaceutical companies and are currently used for vaccination. It is additionally planned to rollout another one – CoviVac.

Despite the pandemic-related challenges, the domestic pharmaceutical companies, in conjunction with research institutes, have managed to accomplish a multitude of objectives in order to deploy new vaccine production sites in a short amount of time, Putin said during a videoconference meeting focused on increasing the manufacturing capacity of COVID-19 vaccines and the progress of vaccination in Russia.

Unreservedly made reference to staff qualities such as consistent and effective hard-work, truly selfless work and responsible attitude, and further urged them to continue making relentless efforts in stabilising the spread of the coronavirus infections and in protecting the life and health of millions of people in the country.

Putin further noted that the implementation of a wide range of preventive measures, including widespread vaccination, has played a significant role in normalising the epidemic situation. Overall, 6.3 million Russians have taken the first part of the vaccine, of these 4.3 million have been vaccinated in full, that is, they have received both vaccine components.

“We can safely say, and the practical results indisputably corroborate, the fact that the Russian vaccines are absolutely safe and dependable. Our success is recognised abroad as well. The number of countries using the Sputnik V vaccine is expanding fast, more countries around the world are showing interest in our vaccine with 55 countries having authorised its use,” he told the meeting.

In addition, Russia now has a number of contracts with foreign manufacturers, – these are foreign manufacturers who will be producing our vaccine on their territory – have been signed for the number of doses needed to vaccinate 700 million people per year. The latest, it has signed a contract with an Indian company for doses to vaccinate 100 million people. Indisputably, working with 55 countries means a total population of 1.4 billion. There are plans to expand the number of partner countries and that will reach estimated 2.5 billion people.

While Russia and its pharmaceutical companies are considering the dynamics of the global market and the demand for Russian-made vaccines, and expanding their production capacities, it equally places emphasis on domestic needs, supplying and vaccinating Russian citizens with vaccines, is an absolute priority. It is estimated that at least 60 percent of all adults in the country must be vaccinated for complete stabilisation. This requires 69.8 million sets of vaccine doses. At any rate, there are more than 20 million Sputnik V doses, according to Russian president, quoting his Prime Minister Mikhail Mishustin.

In his contribution at the meeting, Minister of Industry Denis Manturov informed that under the plan, 12.5 million sets of the vaccine must be produced in March. The planned figure for April is 17 million. It is planned to continue building up production so as to have over 80 million of two-component doses by the first six months.

According to him, all these amounts will be primarily used to vaccinate Russian citizens. In order to meet the global demand for Russian vaccines, his ministry is working on scaling up production of vaccines and on transferring technology abroad. It already has comprehensive agreements on this with manufacturers in 10 countries.

Healthcare Minister Mikhail Murashko informed the meeting about organisations that keep monitoring the virus’s mutations, including those in Russia. “We are analysing the efficiency of medicines for preventing the disease caused by various strains. This work is ongoing continuously and involves several agencies,” he said, and further mentioned the need to increase the speed of vaccination.

By the end of March, our healthcare facilities will receive over 6.5 million dozes of Sputnik V. We expect that a total of some 30 million dozes will be delivered in April and May. As of now, there are 4,500 stationary vaccination stations across Russia, and plans to increase this figure, as well as over 1,000 mobile stations.

Participating in the meeting, Pharmstandard Chairman of the Board Viktor Kharitonin also discussed production capability of the vaccine and pointed to the successful completion of the transfer of laboratory technology, scaled and fine-tuned the manufacturing technology abroad.

“It should be specifically pointed out that, thanks to our cooperation with the Russian Direct Investment Fund, we have started supplying the vaccine to foreign markets. We have already transferred the production technology to Kazakhstan and Belarus and continue working with other countries, including India and Italy. In Italy, Sputnik V was highly praised by both scientists and our colleagues from pharmaceutical companies,” added Kharitonin.

Taking his turn, Chairman of the Board of the R-Pharm Group Alexei Repik talked about efforts that are currently focused on the creation and manufacturing of new forms of the vaccine that will be easier to use and also to transport. He noted that it will increase the attractiveness of the vaccines on foreign markets, including countries with a hot climate: the Middle East, Africa and Latin America.

“Our factory is now producing the first registration batches of a promising lyophilic form of the vaccine created by our experts. It has proved stable at temperatures between +2 and +8 C. We are now studying its stability at room temperature. There are grounds to believe that we will succeed. This form will allow us to make the vaccine available in hard-to-reach regions of the country, which is especially important ahead of the spring and summer period,” informed Alexei Repik.

Director of the Gamaleya National Research Centre for Epidemiology and Microbiology Alexander Gintsburg also highlighted a few aspects of the vaccine production and about documents for registration. According to him, the Gamaleya Research Centre also addresses the problem of expanding the production of the Sputnik Light vaccine.

In addition, as the holder of the registration certificate, the Centre assumes all responsibility for quality control of this vaccine at all enterprises where it is manufactured in this country and abroad.

Moreover, the Centre is directly involved in launching contractual production that is mostly organised by the Russian Direct Investment Fund. The Centre has prepared the entire package of documents for registering the Sputnik Light vaccine in 55 countries. Considering that each country has its own regulatory system, this is not a fixed package of documents that will apply everywhere, therefore it has to adapt it to every country’s regulatory system.

He further spoke about The Lancet, a highly prestigious and popular medical journal, that published two articles on the results of scientific data and clinical trials. This provides important scientific evidence proving the vaccine’s efficacy, this has completely eliminated the Western academic community’ scepticism regarding the vaccines’ quality and efficacy.

Alexander Gintsburg explained a little about children’s vaccination. According to him, children must be divided into several age groups. Russian experts and specialists in paediatric immunology are working in this direction. He said that a vaccine has been developed, patented, and are currently launching clinical trials of Sputnik V’s intranasal form. This is a very gentle and patient-friendly form of vaccination for children, especially little children, who can be traumatised when they see a syringe or when possible side effects arise. The first experiments show that the intranasal form is completely free from any side effects.

CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev stressed patent protection and about protecting intellectual rights for Russian made vaccines and other medical products. “Our patent protection is very strong. We submitted applications early on, much earlier than other countries, and thus got a headstart. Accordingly, the Gamaleya Institute owns the innovations that are available even at these foreign sites, which include over 20 partner companies in 10 countries,” he told the meeting.

On foreign cooperation, “Mr President, I would like to thank you, because it was your idea to build production partnerships with various countries, and 20 manufacturers from over 10 countries responded. For them, it’s about vaccine safety and independence, and Russia was the only country to have come up with this offer. Thank you very much. They are very grateful to you for this,” Kirill Dmitriev said in appreciation.

Director General of the Vektor State Research Centre of Virology and Biotechnology Rinat Maksyutov discussed various research operations. Vektor is the only WHO COVID-19 reference laboratory in Russia. It not only conducts the entire range of viral studies of the novel coronavirus, but is also monitoring its genetic mutations across the country on a regular basis.

“By now, we have found over 5,300 genetic variations across the genome. In the overwhelming number of cases, the replacement does not change the epidemiological characteristics of the virus. At the same time, we have also found over 50 variations of the British strain, three cases of the South African strain and over 20 unique variations of the virus that must be thoroughly studied,” he said.

According to Rinat Maksyutov, the Research Centre Vektor is studying these variations of the virus in accordance with a special algorithm. “We are studying the virus’s stability on various surfaces; we are also using unique equipment, which has no analogues throughout the world, to study the ability of the virus to be transmitted between living organisms. We have found that the British strain of the novel coronavirus can be effectively neutralised by serum taken from those who had COVID and those vaccinated with Sputnik V or EpiVacCorona,” he told the meeting.

Director General of the Chumakov Federal Scientific Centre for the Research and Development of Immune and Biological Products (Russian Academy of Sciences) Aidar Ishmukhametov spoke about their engagement and involvement in research and production of medical products, tracing its roots to the Soviet Union.

The Chumakov Centre is one of the oldest facilities in the Russian Federation and the oldest vaccine developer in Russia. That in the 1960s, this centre’s achievements helped the country deal with polio. The centre back then developed a unique vaccine that supplied to the entire world, including the United States, Europe, Japan and many other countries. In fact, now this facility, the Institute of Poliomyelitis, is well-known around the world.

It is continuing this tradition. As of today, it has developed and produced five vaccines, including for tick-borne encephalitis, rabies and the yellow fever vaccine that is supplied to almost 50 countries, which is perhaps Russia’s biggest export in the pharmaceutical industry.

This type of organisation that has a research and development facility at its core that can outline the task and release a certain number of batches of the vaccine consisting of tens of millions [of doses], on one hand, and well-coordinated work with research institutes and the search for partners, on the other hand, is a very efficient model.

“We did not intend to work exclusively on the coronavirus vaccine. It was important to us to maintain the same production volume and supply vaccines according to the national vaccination calendar as well as deliver on the exports. So we needed to fit this new objective into our existing model. We inherited this research and development facility from the Soviet Union where it was a leader in this industry, and we are developing it,” he underlined the importance of his institution at the meeting.

CEO of the National Immunobiological Company, Rostec State Corporation, Andrei Zagorsky, however, noted that vaccine production is growing steadily. He highlighted the question of warehousing (storage), freezer facility and shipping to the regions. This is carried out in close cooperation with the manufacturing sites, as well as cargo recipients in the regions. These tasks are fulfilled on schedule, he said.

“We monitor the entire production process, especially the temperature, all the way from production, transport, acceptance to a warehouse, storage at the warehouse, to shipment to a recipient region. All products are transported in thermal containers, which can keep temperatures at 18 degrees below zero Celsius for about five days,” he added, speaking at the meeting.

Deputy Prime Minister Tatyana Golikova concluded with high appreciation. The meeting ended with clear understanding in what direction should be moving to overcoming the coronavirus pandemic and at the same time, extend assistance to foreign countries that are in need. She, however, reiterated that, in a fairly short time, despite the difficulties and amid the challenging pandemic of 2020, all her colleagues have indeed accomplished something that seemed almost impossible, worked 24/7 and made Russia the leader in the production and use of vaccines, primarily, for the public in Russia.

MD Africa Editor Kester Kenn Klomegah is an independent researcher and writer on African affairs in the EurAsian region and former Soviet republics. He wrote previously for African Press Agency, African Executive and Inter Press Service. Earlier, he had worked for The Moscow Times, a reputable English newspaper. Klomegah taught part-time at the Moscow Institute of Modern Journalism. He studied international journalism and mass communication, and later spent a year at the Moscow State Institute of International Relations. He co-authored a book “AIDS/HIV and Men: Taking Risk or Taking Responsibility” published by the London-based Panos Institute. In 2004 and again in 2009, he won the Golden Word Prize for a series of analytical articles on Russia's economic cooperation with African countries.

Continue Reading
Comments

Russia

The 30th Anniversary of the Renewal of Diplomatic Relations Between Russia and Israel

Published

on

Minister of Foreign Affairs of the Russian Federation Sergey V. Lavrov’s article for the Israeli Newspaper “Yedioth Ahronoth” dedicated to the 30th Anniversary of the Renewal of Diplomatic Relations Between Russia and Israel, October 15, 2021.

On October 18, Russia and Israel celebrate the 30th anniversary of the renewal of full-fledged diplomatic relations – the beginning of a new era of common history.

Turning to the pages of the past, let me recall that the USSR was the first country to recognize de jure the State of Israel back in May 1948. Of course, there were ups and downs in the chronicle of our relationship. Today, it could be assessed with confidence that Russian-Israeli mutually beneficial cooperation has stood the test of time and continues to actively develop in all directions.

Its foundation is formed by an intensive political dialogue, foremost – at the highest level. Inter-parliamentary contacts are progressing, bolstered by Friendship Groups established in the legislative bodies of our countries. Inter-ministerial communications are carried out on a regular basis.

Over the past decades, a solid experience of diversified cooperation has been accumulated in such spheres as economics, science and technology, healthcare and education. More than twenty acting intergovernmental agreements reflect the richness of the bilateral agenda.

Our mutual practical cooperation has significant potential. A number of joint projects are being successfully implemented. Many initiatives have received the support of the President of the Russian Federation and the Prime Minister of the State of Israel. The interest of Israeli business circles in entering the Russian market continues to grow. Despite the consequences of the coronavirus pandemic, by the end of 2020 trade between Russia and Israel decreased by only 3.9%, and in January-July this year it increased by 51.8% over the previous year’s period. The key coordinating mission in these common efforts is fulfilled by the Joint Russian-Israeli Commission for Trade and Economic Cooperation, founded in 1994. We are interested in the early resumption of its work in full.

A special role in strengthening the unifying baselines of our relations as well as ensuring their stability and continuity belongs to humanitarian contacts. We appreciate the high level of mutual understanding between the peoples of Russia and Israel, connected by a common historical memory and convergence of cultures. It is encouraging that this thread, which has no geographic boundaries, is only getting stronger in course of time.

There are millions of Russian-speaking compatriots living in Israel, including descendants both from the former Republics of the USSR and from the Russian Federation. Veterans of the Great Patriotic War, survivors of the siege, former prisoners of concentration camps are among them. The fate of these people is of major interest to us.

Most vigorous rejection of the attempts of historical revisionism, combatting the distortion of the genesis, course and generally recognized international legal outcomes of the World War II have always united Russia and Israel. We will continue to coordinate our efforts, and specifically at the UN, to counter this shameful phenomenon.

While in some countries of Central and Eastern Europe Nazi henchmen are being brought to the level of national heroes and neo-Nazi tendencies are being revived, the memory of the decisive contribution of the heroic soldiers of the Red Army to the Victory over Nazism, the saving of Jews and other peoples from extermination, the liberation of the world from the horrors of the Holocaust is sacred in Israel. We see how Israeli colleagues – at the state and public levels – encourage the activities of the veterans and compatriots movements, conduct active work to educate the younger generation.

It is difficult to overestimate the significance of the law on Celebrating the Victory Day over Nazi Germany on May 9, approved by the Israeli parliament in 2017. It is particularly telling that on the 76th anniversary of the Great Victory, celebrated this year, festive events and commemorative parades along with the Immortal Regiment march were held in more than 45 Israeli cities. Thousands of Israelis of all ages as well as officials participated. This scale speaks for itself.

Cooperation in the field of education and science – whether through student and academic exchanges or joint scientific research continues to move forward. Every year, students from Israel get an opportunity to receive higher education in Russian universities. All of them are sincerely welcome there.

We hope that it will be possible to restore mutual tourist flows as soon as the sanitary and epidemiological situation improves. Russia is traditionally one of the top three countries in terms of the number of visitors to Israel.

The Russian-Israeli dialogue is vigorously advancing through the foreign ministries. It is obvious that without constructive interaction of diplomats it is impossible to solve a number of international and regional problems that are of paramount importance both for ensuring the prosperous future of the peoples of Russia and Israel just as for strengthening international and regional security and stability. From this perspective, diversified contacts between the Security Councils and the defense ministries of our countries have also proven themselves well. On a regular basis it allows us to compare approaches and take into account each other’s legitimate interests.

Russia is pursuing an independent multi-vector foreign policy, contemplating pragmatism, the search for compromises and the observance of balances of interests. Creation of the most favorable external conditions for our internal socio-economic development remains its backbone. We have no ideological likes and dislikes, or any taboos in relations with our foreign partners, therefore we can play an active role in the international arena and specifically through mediation in the settlement of conflicts.

We are interested in continuing consultations with our Israeli partners on security and stability issues in the Middle East. We always draw attention to the fact that comprehensive solutions to the problems of the region must necessarily take into account the security interests of Israel. This is a matter of principle.

At the same time, we are convinced that there is no alternative to the two-state solution of the Israeli-Palestinian conflict on a generally recognized international legal basis. We strongly support direct negotiations between Israelis and Palestinians. A comprehensive solution to all issues of the final status is possible only through it. We are ready to work with Israeli colleagues, including multilateral formats, primarily in the context of the renewal of work of the Middle East Quartet of international mediators in close cooperation with representatives of the Arab League.

I am convinced: it is in the common interest to maintain the momentum. Ahead of us are new milestones and additional opportunities not only to continue, but also to enrich the positive experience of multifaceted cooperation for the benefit of our states and peoples, in the interests of peace and stability.

Source: Minister of Foreign Affairs

Continue Reading

Russia

The Emerging “Eastern Axis” and the Future of JCPOA

Published

on

Iranian Foreign Ministry spokesperson, Saeed Khatibzadeh recently said that Tehran would further strengthen its ties with Moscow via a strategic partnership. Said Khatibzadeh  ‘The initial arrangements of this document, entitled the Global Agreement for Cooperation between Iran and Russia, have been concluded’

    This agreement will be similar in nature to the agreement signed by Iran with China in March 2021, dubbed as the strategic cooperation pact, which sought to enhance economic and strategic relations (China would invest 400 Billion USD in infrastructure and oil and gas sector while also strengthening security ties). Commenting on the same, Khatibzadeh also said that an ‘Eastern axis’ is emerging between Russia, Iran and China.

    Closer ties with Russia are important from an economic, strategic point of view, and also to reduce Iran’s dependence upon China (many including Iran’s Foreign Minister had been critical of the 25 year agreement saying that it lacked transparency). Iranian Foreign Minister, Hossein Amir-Abdollahian on the eve of his Russia visit from October 5-6th, 2021 also stated that Iran while strengthening ties would not want to be excessively dependent upon either country.

Iranian Foreign Minister’s visit to Russia

    Iranian Foreign Minister, Hossein Amirabdollahian  during his Russia visit  discussed a host of issues with his Russian counterpart, Sergey Lavrov including the current situation in Afghanistan, South Caucasus, Syria and the resumption of the Vienna negotiations.

Russia and Iran have been working closely on Afghanistan (on October 20, 2021 Russia is hosting talks involving China, India, Iran and Pakistan with the Taliban).

It is also important to bear in mind, that both Russia and Iran have flagged the non-inclusive nature of the Taliban Interim government. Russia has in fact categorically stated that recognition of Taliban was not on the table. Said the Russian Foreign Minister, Sergey Lavrov on the sidelines of the United Nations General Assembly,   ‘the whole gamut of Afghan society — ethno-religious and political forces — so we are engaging in contacts, they are ongoing.’

China’s approach vis-à-vis Afghanistan

Here it would be pertinent to point out, that China’s stance vis-à-vis Afghanistan is not identical to that of Moscow and Tehran. Beijing while putting forward its concerns vis-à-vis the use of Afghan territory for terrorism and support to Uyghur separatist group East Turkestan Islamic Movement (ETIM), has repeatedly said that there should be no external interference, and that Afghanistan should be allowed to decide its future course. China has also spoken in favor of removal of sanctions against the Taliban, and also freeing the reserves of the Afghan Central Bank (estimated at well over 9 Billion USD), which had been frozen by the US after the takeover of Afghanistan by the Taliban.

If one were to look at the Joint Comprehensive Plan of Action JCPOA/Iran Nuclear deal, Russia has been urging Iran to get back to the Vienna negotiations on the one hand (these negotiations have been on hold since June), while also asking the US to return to its commitments, it had made under the JCPOA, and also put an end to restriction on Iran and its trading partners.

Conversation between US Secretary of State and Russian Foreign Minister

The important role of Russia is reiterated by the conversation between US Secretary of State Anthony Blinken with Russian Foreign Minister. Angela Merkel during her visit to Israel also made an important point that both China and Russia had an important role to play as far as getting Iran back on JCPOA is concerned. What is also interesting is that US has provided a waiver to the company building the Nord Stream 2 pipeline connecting Russia and Germany. The US has opposed the project, but the Department of State said waiving these sanctions was in US national interest. Both Germany and Russia welcomed this decision.

In conclusion, while there is no doubt that Russia may have moved closer to China in recent years, its stance on Afghanistan as well as it’s important role in the context of resumption of Vienna negotiations highlight the fact that Moscow is not keen to play second fiddle to Beijing. The Biden Administration in spite of its differences has been engaging closely with Moscow (a number of US analysts have been arguing for Washington to adopt a pragmatic approach vis-à-vis Russia and to avoid hyphenating Moscow with Beijing).  In the given geopolitical landscape, Washington would not be particularly averse to Tehran moving closer to Russia. While the Iranian spokesperson, Saeed Khatibzadeh spoke about a Eastern axis emerging between Moscow, Tehran and Beijing, it would be pertinent to point out, that there are differences on a number of issues between Moscow and Beijing. The Russia-Iran relationship as well as US engagement with Russia on a number of important geopolitical issues underscores the pitfalls of viewing geopolitics from simplistic binaries.

Continue Reading

Russia

New U.S. travel rules excludes foreigners vaccinated with Russia’s Sputnik V

Published

on

Local and foreign media have stepped up reports about rising Covid-19 infections in Russia. While the reports also indicated high deaths in the country, other highligted new trends that are noticeably appearing. Interestingly, directors at the Russian tourism and travel agencies say that many Russians are lining up for vaccine tourism in Serbia, Bulgaria and Germany and a few other foreign countries.

These Russians aim at getting foreign vaccines including Pfizer, Moderna and Johnson & Johnson and AstraZeneca.

Here are a few facts about Russian vaccines.

Russia’s Sputnik V was the first officially registered coronavirus vaccine on August 11, 2020. Russia is using four vaccines for mass vaccination for Covid-19. These are Sputnik V and Sputnik Light developed by the Russian Health Ministry’s Gamaleya Center.

EpiVacCorona developed by the Vector Center of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), and CoviVac developed by the Chumakov Institute of the Russian Academy of Sciences.

Clinical trials of the EpiVacCorona vaccine on teens aged from 15 to 17 might begin in the near future.

China has 1.3 billion population and has given the two billionth vaccine by the end of August, the United State has 380 million and attained 60% of its population. In Europe, vaccination rate is highly at an appreciable level.

Overall, Russia with an estimated 146 million people has Europe’s highest death toll from the pandemic, nearly 210,000 people as at September 30, according to various authentic sources including the National Coronavirus Task Force.

More than 42 million Russians have received both components of a coronavirus vaccine, according to Russian Deputy Prime Minister Tatyana Golikova.

“The number of citizens who have received the first component of a vaccine has topped 44 million, and more than 37 million people have completed a full vaccination course,” Golikova said.

She gave an assurance back in July that once the population have been immunized with at least the first component of a two-shot vaccine, herd immunity to Covid-19, or at least an 80% vaccination rate, should be reached by November 1.

Reasons: Even though Russia boasted of creating the world’s first coronavirus vaccines, vaccination is very low. Critics have principally blamed a botched vaccine rollout and mixed messages the authorities have been sending about the outbreak.

In addition, coronavirus antibody tests are popular in Russia and some observers suggest this contributes to the low vaccination numbers.

Western health experts say the antibody tests are unreliable either for diagnosing Covid-19 or assessing immunity to it. The antibodies that these tests look for can only serve as evidence of a past infection. Scientists say it’s still unclear what level of antibodies indicates that a person has protection from the virus and for how long.

Russia has registered Sputnik V in more than 150 foreign countries. The World Health Organization is yet to register this vaccine. For its registration, it must necessarily pass through approved procedures, so far Russia has ignored them, according reports.

There have also been several debates after the World Health Organization paused its review process of the Sputnik V vaccine over concerns about its manufacturing process, and few other technical reasons. While some talked about politicizing the vaccine registration, other have faced facts of observing recognized international rules for certifying medical products as such vaccines.

During the first week of October, Russian Health Minister Mikhail Murashko has reiterated or repeated assertively that a certain package of documents were needed to continue the process for the approval of the Russian coronavirus vaccine Sputnik V by the World Health Organization. The final approval is expected towards the end of 2021.

Still some the problems with the registration as unfair competition in the global market. For instance, Russian Minister of Industry and Trade Denis Manturov said in an interview with the Rossiya-24 television channel on October 5: “I think it is an element of competition. Until Pfizer covers a certain part of the market, it is pure economics.”

On the other side, Pyotr Ilyichev, Director for International Organization at the Russian Foreign Affairs Ministry, told Interfax News Agency, for instance that World Health Organization has been playing politics around Russian vaccine especially when it is need in most parts of the world.

“The world is facing an acute shortage of vaccines for the novel coronavirus infection. In certain regions, for instance in African countries, less than 2% of the population has been vaccinated. The Russian vaccine is in demand, and the UN stands ready to buy it,” he told Interfax.

“However, certification in the WHO is a complex, multi-step process, which was developed in the past in line with Western countries’ standards. It requires time and serious efforts from our producers. We hope that this process will be successfully finalized in the near future,” Ilyichev said.

Chairman of the State Duma’s Foreign Affairs Committee Leonid Slutsky has described as discriminatory a decision reported by foreign media that the United States, under its new consular rules, would deny entry for foreigners immunized with the Russian Covid-19 vaccine Sputnik V.

“Thus, the U.S. will blatantly embark on a path of ‘vaccine discrimination.’ There are absolutely no grounds for such decisions. The efficacy and safety of the Sputnik V vaccine have been confirmed not only by specialists, but also by its use in practice,” Slutsky said on Telegram.

He cited an article in The Washington Post saying that from November the United States may begin denying entry to foreigners vaccinated with Sputnik V.

It means that if such additional border measures are adopted, foreigners seeking entry to the United States will have to be immunized with vaccines approved for use either by American authorities or the World Health Organization.

According to an article published in The Washington Post, for the first time since the pandemic began, the United States intends to loosen entry restrictions for foreigners vaccinated against Covid-19.

The new rules, which enter into force in November, will not apply to Russians vaccinated with Sputnik V and citizens of other countries using this Russian vaccine.

Under the new rules, foreigners will enter United States only if they are immunized with vaccines approved for use by the United States Food and Drug Administration or the World Health Organization. Russia’s Sputnik V is yet to be approved by the World Health Organization and is not recognized by the United States.

Continue Reading

Publications

Latest

Trending